Secondary

endpoints included the blood-pressure-lowering efficacy and the overall safety and tolerability of valsartan at Weeks 4 and 12. Results. The monotherapy and combination groups had comparable baseline characteristics. At Week 4, monotherapy was found non-inferior to combination for incidence rate of dizziness (monotherapy, 9.25%; combination, 10%; difference in incidence of dizziness, 0.75%; 95% CI – 0.61% to 2.12%; non-inferiority margin, HSP990 solubility dmso -1.33%; Wald Test approach). Greater blood pressure (BP) reduction was noted at Week 12 than at Week 4. The antihypertensive effect was greater with combination therapy and the 160-mg dose. BP control (systolic <140 mmHg or diastolic <90 mmHg) was achieved in 80-90% patients. Valsartan was well tolerated; most commonly reported adverse events included dizziness, headache, constipation and cough. Conclusion. Valsartan is an effective treatment option for essential hypertension in Taiwanese patients.”
“Schizophrenia is a severe psychiatric disorder with frequent recurrent AZD8055 cell line psychotic relapses and progressive functional impairment. It results from a poorly understood gene-environment interaction. The gene encoding catechol-O-methyltransferase (COMT) is a likely candidate for schizophrenia. Its rs165599 (A/G) polymorphism has been shown to be associated with alteration of COMT gene expression. Therefore, the present study aimed to investigate a possible association

between schizophrenia and this polymorphism. The distribution of the alleles and genotypes of this polymorphism was investigated in a Brazilian sample of

245 patients and 834 controls. The genotypic frequencies were in Hardy-Weinberg equilibrium and no statistically significant differences were found between cases and controls when analyzed according to gender or schizophrenia subtypes. There was also no difference in homozygosis between cases and controls. Thus, in the sample studied, there C188-9 clinical trial was no evidence of any association between schizophrenia and rs165599 (A/G) polymorphism in the non-coding region 3′ of the COMT gene.”
“Aim:

The purpose of this study was to clarify the risk of rubella infection for pregnant women in the outbreak area.

Material & Methods:

We performed a retrospective, population-based study on all 232 pregnant women during the rubella outbreak period in Tokunoshima Island. All women had a rubella hemagglutination inhibition (HI) titer drawn during their current pregnancy. In 61 women, HI titers were compared between the current and past pregnancies. Rubella IgG antibody titers were measured and IgG avidity index (AI) was calculated for 92 non-infected pregnant women.

Results:

Of the 232 candidates, 22 pregnant women contracted rubella infection (congenitally infected infants: 2). Seventeen of 61 pregnant women showed a four-fold or greater elevation in HI titer when compared with previous titers. Their previous HI titers were all < 64.